• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·China·Healthcare·603590.SS
Share

Beijing Konruns Pharmaceutical Co.,Ltd. Stocks

CN¥ 25.66Last Updated 06.11.2026

Issuer Rating

4/7
Performance

Average

Risk

Moderate

Recommendation

Hold

Market Cap

CN¥ 593.30M

CN¥ 25.66
Key Takeaways

Risk factor

High price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Fairly valued vs peers

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Beijing Konruns Pharmaceutical Co.,Ltd., a Chinese company established in 2003 and based in Beijing, focuses on the discovery, production, and distribution of various pharmaceutical items. Among its key offerings is Su Ling, a hemagglutinin preparation designed to minimize blood loss during surgical procedures and manage post-operative bleeding. The firm is also actively developing a pipeline of potential new medicines, such as CX1026, CX1003, and KC1036.

Company Valuation

Fairly valued
4/7

Based on key historical and expected multiples, the stock is fairly valued relative to its peers. In particular, the stock is reasonably priced on P/E, of fair value on E

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

08.11.2026 15:01

Getting Stuck on the Same Thing: How News Concentration Affects Investors' Decisions

07.11.2026 23:21

'Air is coming out of the AI bubble': Strategists urge investors to buy after rout

07.11.2026 19:13

Berkshire has sharply accelerated its share buybacks. Should investors buy these shares?

07.11.2026 17:01

Small caps last week: Inovio approval, Alstom guidance cut, Once Upon a Farm recall

07.11.2026 13:01

A Blow to Elon Musk, “Guppy Fry” in the Ocean of AI, Kazakhstan’s Radioactive Armor

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026